Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Inventory: 2022-2024

Historic Inventory for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $15.7 million.

  • Axsome Therapeutics' Inventory rose 66.66% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 66.66%. This contributed to the annual value of $15.7 million for FY2024, which is 3.94% up from last year.
  • As of FY2024, Axsome Therapeutics' Inventory stood at $15.7 million, which was up 3.94% from $15.1 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Inventory ranged from a high of $15.7 million in FY2024 and a low of $4.3 million during FY2022.
  • In the last 3 years, Axsome Therapeutics' Inventory had a median value of $15.1 million in 2023 and averaged $11.7 million.
  • Data for Axsome Therapeutics' Inventory shows a peak YoY spiked of 250.35% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Axsome Therapeutics' Inventory stood at $4.3 million in 2022, then surged by 250.35% to $15.1 million in 2023, then climbed by 3.94% to $15.7 million in 2024.